About this trial
Prospective, single-centre study with the central question of how the metabolome from blood samples, different body fluids and tissues between patients patients with malignant melanoma in different tumour tumour stages and healthy patients and whether this is suitable for early detection of initial diagnosis, recurrence or stage shift at an early stage.
The biosamples are collected in the BioBank Dresden and used for the NMR and LC-MS analyses described here. It is planned to use the biosamples for further analyses.
Eligibility criteria
Qualifiers
Current or past history of melanoma
Ongoing therapy or tumour aftercare at the Skin Cancer Centre at Dresden University Hospital
Disqualifiers
Refusal to participate in the study
Lack of capacity to consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Technische Universität Dresden
Lead sponsor
University Hospital Carl Gustav Carus
Sponsor institution
University Hospital Carl Gustav Carus
Collaborator